Form 4: Lemaitre Vascular Senior VP Reports Routine Acquisition of Dividend Equivalent Rights

Trent G. Kamke, Senior V.P., Operations at Lemaitre Vascular Inc., reported the acquisition of various dividend equivalent rights tied to his restricted stock and performance share unit awards on May 29, 2025, as part of his ongoing compensation.

Summary

• Trent G. Kamke, Senior V.P., Operations of Lemaitre Vascular Inc. (LMAT), filed a Form 4 reporting changes in his beneficial ownership.
• The filing details the acquisition of several tranches of Dividend Equivalent Rights (DERs) on May 29, 2025.
• These DERs accrued on previously granted Restricted Stock Unit (RSU) awards and Performance Share Unit (PSU) awards, with grant dates ranging from December 2, 2020, to December 6, 2024.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with the underlying RSU or PSU award.
• The acquired DER amounts include 0.4037, 0.737, 1.5004, 1.5004, 1.9242, 2.3061, and 2.2923 units.
• Following these transactions, Mr. Kamke's beneficial ownership of these specific DERs stands at 12.4206, 12.9976, 14.0522, 14.0438, 9.8373, 10.5875, and 4.5015 units, respectively.

Sentiment

Score: 7

Explanation: The document reports a routine executive compensation event (accrual of dividend equivalent rights), which is generally neutral but can be seen as slightly positive due to ongoing alignment of executive and shareholder interests through equity participation.

Positives

• The acquisition of Dividend Equivalent Rights aligns the executive's financial interests with those of shareholders, as these rights are tied to the company's common stock.
• This filing represents a routine and expected part of executive compensation, indicating stability in the company's incentive programs.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing details a routine executive compensation event, specifically the accrual of dividend equivalent rights on equity awards. Such compensation structures, involving restricted stock units and performance share units with associated dividend equivalents, are common across various industries, including the medical device sector, to incentivize long-term executive performance and align management interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) as components of executive compensation, along with the accrual of Dividend Equivalent Rights (DERs), is a widely adopted practice across publicly traded companies, including those in the medical technology and vascular device sectors.
• This compensation structure is consistent with global benchmarks for executive incentive plans, aiming to foster long-term commitment and performance alignment.
• While specific comparable companies or projects are not detailed in this filing, the mechanism itself is standard for executive equity compensation in companies like Medtronic, Boston Scientific, or Edwards Lifesciences, which also utilize similar long-term incentive vehicles.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights aligns the interests of Senior V.P., Operations Trent G. Kamke with shareholders, as his compensation is increasingly tied to the company's stock performance and dividend policy.

Next Steps

• The dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards, leading to potential future conversion into common stock.

Key Dates

Recommendation

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Executive Compensation, Trent G. Kamke